KAIST Identifies RNASEK Enzyme That Extends Lifespan by Clearing Circular RNA

Why It Matters

The discovery of RNASEK’s role in clearing circular RNA reframes a long‑standing biomarker as an active driver of cellular aging. For the biohacking ecosystem, it opens a concrete molecular target that can be measured, modulated, and potentially combined with existing longevity stacks. On a broader scale, the work suggests that RNA‑based waste management is a viable therapeutic axis, expanding the drug discovery landscape beyond protein‑centric approaches. If RNASEK‑targeted therapies prove safe in humans, they could delay the onset of age‑related diseases such as neurodegeneration, sarcopenia, and metabolic decline. This would have profound socioeconomic implications, reducing healthcare costs associated with an aging population and reshaping public health strategies around preventive longevity.

Key Takeaways

• KAIST team identified RNASEK enzyme as a key degrader of circular RNA.
• Increasing RNASEK expression extended lifespan by ~30% in C. elegans.
• RNASEK deficiency caused stress‑granule formation and premature aging in mouse and human cells.
• Study published in *Molecular Cell* on Feb 24 2026, with co‑first authors Ham Seok‑jin and Boo Seong‑ho.
• Potential for RNASEK‑based therapeutics to join emerging anti‑aging drug pipelines.

Pulse Analysis

RNASEK’s emergence as a longevity factor marks a shift from the protein‑centric view of aging to a more nuanced RNA‑centric paradigm. Historically, interventions have targeted DNA damage, senescent cell clearance, or metabolic pathways. Circular RNA, once dismissed as a passive by‑product, now appears to be a toxic waste that, when unchecked, accelerates cellular decline. This aligns with recent discoveries that non‑coding RNAs can modulate stress responses and proteostasis, suggesting a broader regulatory network that biohackers and biotech firms have yet to exploit.

From a market perspective, the timing is ripe. The anti‑aging sector has attracted billions in venture capital, yet few candidates have progressed beyond early‑stage trials. RNASEK offers a dual‑action mechanism—RNA degradation and chaperone support—that could differentiate future therapeutics from existing senolytics or NAD+ precursors. Companies that can develop selective RNASEK activators or gene‑editing approaches may capture a premium in a market hungry for clinically validated longevity solutions.

However, the path to commercialization is fraught with challenges. RNA‑targeted drugs must navigate delivery hurdles, off‑target effects, and regulatory uncertainty around “life‑extension” claims. Moreover, the translational gap between nematodes and humans remains large; what works in a worm’s simple system may not scale to complex mammalian physiology. The next few years will test whether RNASEK can move from a compelling laboratory finding to a viable therapeutic, and whether the biohacking community can responsibly integrate such interventions into DIY health regimens.